Clinical significance of hepatitis B virion and SVP productivity: Relationships between intrahepatic and serum markers in chronic hepatitis B patients

United European Gastroenterology Journal

Volumn 2, Issue 2, 2014, Pages 91-98

  Lesmana, Cosmas Rinaldi Adithya ^a,d   Jackson, Kathy ^b   Lim, Seng Gee ^c   Sulaiman, Ali ^a   Pakasi, Levina S ^d   Gani, Rino A ^a   Hasan, Irsan ^a   Sulaiman, Andri Sanityoso ^a   Lesmana, Laurentius A ^a,d   Hammond, Rachel ^b   Revill, Peter ^b   Locarnini, Stephen ^b   Bowden, Scott David ^b  

^a CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^b North Melbourne   (Australia)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d Medistra Hospital   (Indonesia)

Author keywords

Chronic hepatitis B; Intrahepatic cccDNA; Quantitative HBsAg; Subviral particles productivity; Total HBV DNA; Virion productivity

Indexed keywords

COMPLEMENTARY DNA; HEPATITIS B(E) ANTIGEN; RNA; VIRUS DNA;

ADULT; AGED; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CHRONIC HEPATITIS B; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE MUTATION; GENE REPLICATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA EXTRACTION; SEQUENCE ANALYSIS; VIRION; VIRUS PARTICLE; VIRUS REPLICATION;

EID: 85006208442     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640614525151     Document Type: Article

References (27)

1. Lok ASF and McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
3. Liauw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
4. Mommeja-Marin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309-1319.
5. Nassal M and Schaller H. Hepatitis B virus replication -an update. J Viral Hepat 1996; 3: 217-226.
6. Seeger C and Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
7. Summers J and Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-115.
8. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133: 843-852.
9. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758.
10. Wursthron K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684.
11. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahe-patic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
12. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemilu-minescent microparticle immunoassay. J Virol Methods 2004; 115: 217-222.
13. Moucari R and Marcellin P. Quantification of hepatitis B surface antigen: a new conceptfor the management of chronic hepatitis B. Liver Int 2011; 31(Suppl. l): 122-128.
14. Lu L, Ye D, Wang Y, et al. Correlation between HBV cccDNA and HBsAg levels an their reduction by pegin-terferon alfa-2a based therapy in patients with chronic hepatitis B. Hepatology 2008; 48(Suppl. l): 746A.
15. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-1241.
16. Pujol FH, Navas MC, Hainaut P, et al. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett 2009; 286: 80-88.
17. Utama A, Purwantono S, Siburian MD, et al. Hepatitis B virus subgenotypes and basal core promoter mutations in Indonesia. World J Gastroenterol 2009; 15: 4028-1036.
18. Ayres A, Locarnini S and Bartholomeusz A. HBV geno-typing and analysis for unique mutations. Methods Mol Med 2004; 95: 125-149.
19. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
20. Bedossa P and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996; 24: 289-293.
21. Laras A, Koskinas J, Dimou E, et al. Intrahepatic levels and replicative acitivity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006; 44: 694-702.
22. Lesmana LA, Leung NWY, Mahachai V, et al. Hepatitis B: overview of the burden of disease in the Asia-Pacific region. Liver Int 2006; 26: 3-10.
23. Wong DKH, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatol 2004; 40: 727-737.
24. Kramvis A and Kew MC. The core promoter of hepatitis B virus. J Viral Hepat 1999; 6: 415-427.
25. Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592.
26. Chan HLY, Thompson A, Peignoux MM, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011 - a core group report. J Hepatol 2011; 55: 1121-1131.
27. Pollicino T, Amaddeo G, Restuccia A, et al. Impact of hepatitis B virus (HBV) PreS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology 2012; 56: 434-443.